This move to further revise the prices will go a long way in helping patients during these critical times.
Speaking on the development Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, “Through the course of this pandemic, our efforts have been focused on making therapies accessible and affordable to people.
Remdac has been one of the critical drugs in the disease management on COVID and we hope that this price cut will enable people from every strata of the society to access this critical drug.”
In June 2020, Zydus entered into a non-exclusive agreement with Gilead Sciences, to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19.
The API for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat.
Cadila Healthcare ended at Rs426.30 apiece down by Rs4.75 or 1.1% on Sensex.